{
    "Clinical Trial ID": "NCT01011218",
    "Intervention": [
        "INTERVENTION 1: ",
        "  BBT-I + Armodafinil",
        "  Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.",
        "  Armodafinil 150 mg/day by mouth.",
        "  BBT-I: Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone",
        "  Armodafinil: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.",
        "INTERVENTION 2: ",
        "  Behavioral Placebo + Armodafinil",
        "  Control behavioral intervention is a sleep hygiene handout completed by participant.",
        "  Armodafinil 150 mg/day by mouth.",
        "  Control: Control behavioral intervention is a sleep hygiene handout completed by participant.",
        "  Armodafinil: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil."
    ],
    "Eligibility": [
        "INCLUSION CRITERIA",
        "  Be scheduled for cancer treatment with chemotherapy or biologics (prior chemotherapy and/or diagnosis of metastatic breast are allowed)",
        "  Have at least 6 weeks of treatment remaining",
        "   21 years old",
        "  Able to understand written and spoken English",
        "  Able to swallow medication (until amendment omitting armodafinil treatment)",
        "  Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia Severity Index (ISI)",
        "  EXCLUSION CRITERIA",
        "  Prior treatment with armodafinil or modafinil (until amendment omitting armodafinil treatment)",
        "  Prior treatment with psycho-stimulant medication within the past 28 days (until amendment omitting armodafinil treatment)",
        "  Prior treatment with antiseizure medications (until amendment omitting armodafinil treatment)",
        "  Has continuously taken sleep medication daily for the last 28 days (until amendment omitting armodafinil treatment)",
        "  History (self-reported) of unstable medical or psychiatric illness (within the last 5 years)",
        "  History of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or seizures (until amendment omitting armodafinil treatment)",
        "  Pregnant or nursing",
        "  History of substance abuse or meet criteria for current alcohol abuse or dependence",
        "  History (self-reported) of chronic, preexisting insomnia, sleep apnea, or restless leg syndrome (RLS)",
        "  Severe hepatic impairment (until amendment omitting armodafinil treatment)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Insomnia Severity Index (ISI)",
        "  Insomnia Severity Index (ISI) survey questionnaire is a 7-question survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. The full range of ISI scores is from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia. Clinical interpretation is as follows.",
        "  0 to 7 No clinically significant insomnia",
        "  8 to14 Subthreshold insomnia",
        "  15 to 21 Clinical insomnia (moderate severity)",
        "  22 to 28 Clinical insomnia (severe)",
        "  ISI survey was conducted at baseline, 3 weeks, 6 weeks, 10 weeks, and 32 weeks. The outcome is reported as the mean ISI score with standard deviation.",
        "  Time frame: up to 32 Weeks",
        "Results 1: ",
        "  Arm/Group Title: BBT-I + Armodafinil",
        "  Arm/Group Description: Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.",
        "  Armodafinil 150 mg/day by mouth.",
        "  BBT-I: Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone",
        "  Armodafinil: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.",
        "  Overall Number of Participants Analyzed: 9",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  Baseline: 9 participants",
        "  16.3         (7.4)",
        "  3 Weeks: 2 participants",
        "  13.0         (7.1)",
        "  6 Weeks: 6 participants",
        "  9         (6.1)",
        "  10 Weeks: 4 participants",
        "  6.0         (3.6)",
        "  32 Weeks: 1 participants",
        "  3.0  [1]        (NA)",
        "Results 2: ",
        "  Arm/Group Title: Behavioral Placebo + Armodafinil",
        "  Arm/Group Description: Control behavioral intervention is a sleep hygiene handout completed by participant.",
        "  Armodafinil 150 mg/day by mouth.",
        "  Control: Control behavioral intervention is a sleep hygiene handout completed by participant.",
        "  Armodafinil: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.",
        "  Overall Number of Participants Analyzed: 9",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  Baseline: 9 participants",
        "  14.6         (6.3)",
        "  3 Weeks: 9 participants",
        "  10.8         (6.5)",
        "  6 Weeks: 9 participants",
        "  10         (6.9)",
        "  10 Weeks: 9 participants",
        "  8.3         (5.6)",
        "  32 Weeks: 9 participants",
        "7.6         (4.4)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/9 (11.11%)",
        "  Death, not otherwise specified 0/9 (0.00%)",
        "  Pain, bone 1/9 (11.11%)",
        "Adverse Events 2:",
        "  Total: 1/9 (11.11%)",
        "  Death, not otherwise specified 1/9 (11.11%)",
        "  Pain, bone 0/9 (0.00%)"
    ]
}